Celldex price target raised to $15 from $9 at Jefferies Jefferies increased its price target on Celldex as the firm believes that the company's pipeline outlook was encouraging. The firm views Celldex as a compelling biotech play with multiple shots on goal and it maintains a Buy rating.
Celldex rindopepimut receives FDA breakthrough therapy designation Celldex Therapeutics announced that the FDA has granted rindopepimut Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM. This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment in December of 2014.